ALLIANCEBERNSTEIN L.P. - ACHILLION PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of ACHILLION PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2019$6,592,000
+847.1%
1,093,199
+465.3%
0.00%
Q3 2019$696,000
+21.3%
193,400
-9.7%
0.00%
Q2 2019$574,000
-1.5%
214,100
+8.7%
0.00%
Q1 2019$583,000
+85.1%
196,900
-0.7%
0.00%
Q4 2018$315,000
-53.7%
198,300
+7.1%
0.00%
Q3 2018$681,000
+30.0%
185,1000.0%0.00%
Q2 2018$524,000
-11.2%
185,100
+16.3%
0.00%
Q1 2018$590,000
+45.0%
159,100
+12.5%
0.00%
Q4 2017$407,000
-47.1%
141,400
-17.4%
0.00%
-100.0%
Q3 2017$769,000
-2.2%
171,2000.0%0.00%0.0%
Q2 2017$786,000
+1.8%
171,200
-6.7%
0.00%0.0%
Q1 2017$772,000
-6.7%
183,400
-8.5%
0.00%0.0%
Q4 2016$827,000
-49.0%
200,363
+0.1%
0.00%0.0%
Q3 2016$1,622,000
+3.8%
200,2000.0%0.00%0.0%
Q2 2016$1,562,000
+1.0%
200,2000.0%0.00%0.0%
Q1 2016$1,546,000
-27.8%
200,200
+0.9%
0.00%
-50.0%
Q4 2015$2,140,000
+53.5%
198,340
-1.7%
0.00%
+100.0%
Q3 2015$1,394,000
-95.7%
201,700
-94.5%
0.00%
-96.3%
Q2 2015$32,446,000
-9.2%
3,662,082
+1.0%
0.03%
-6.9%
Q1 2015$35,736,000
+1655.2%
3,624,331
+2080.7%
0.03%
+1350.0%
Q4 2014$2,036,000
+6.7%
166,200
-13.1%
0.00%0.0%
Q3 2014$1,908,000
+31.9%
191,2000.0%0.00%
+100.0%
Q2 2014$1,447,000
+199.0%
191,200
+29.9%
0.00%
Q1 2014$484,000
+0.8%
147,200
+1.8%
0.00%
Q4 2013$480,000
-14.3%
144,600
-22.0%
0.00%
-100.0%
Q3 2013$560,000
-61.5%
185,500
+4.3%
0.00%
-50.0%
Q2 2013$1,454,000177,7970.00%
Other shareholders
ACHILLION PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
RA Capital Management 13,633,220$57,396,0007.04%
HealthInvest Partners AB 497,807$2,096,0003.21%
BVF INC/IL 3,285,400$13,832,0002.35%
EMORY UNIVERSITY 486,438$2,048,0001.93%
Marcus Capital, LLC 69,400$1,751,0001.63%
DAFNA Capital Management LLC 196,500$827,0000.70%
Orbimed Advisors 13,107,200$55,181,0000.62%
Rock Springs Capital Management LP 1,500,000$6,315,0000.36%
Spark Investment Management LLC 710,100$2,989,0000.19%
TURNER INVESTMENTS LLC 65,420$275,0000.18%
View complete list of ACHILLION PHARMACEUTICALS IN shareholders